Merck Submits New Data To FDA On Gardasil Use In Women 27-45

The Wall Street Journal

January 13, 2010

Merck & Co. (MRK) said Wednesday it has submitted new clinical data to U.S. regulators in the hopes of expanding use of cervical-cancer vaccine Gardasil to women ages 27 to 45.

Merck submitted the data to the U.S. Food and Drug Administration before the end of 2009, the Whitehouse Station, N.J., drug maker said …



Author: Leslie Carol Botha

Author, publisher, radio talk show host and internationally recognized expert on women's hormone cycles. Social/political activist on Gardasil the HPV vaccine for adolescent girls. Co-author of "Understanding Your Mood, Mind and Hormone Cycle." Honorary advisory board member for the Foundation for the Study of Cycles and member of the Society for Menstrual Cycle Research.